Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.

Jessicca M. Rege, Ph.D. is the Chief Executive Officer of Sus Clinicals, Inc., a biotech accelerating cancer drug development through the Oncopig Cancer Model, an FDA-cleared, genetically engineered pig platform for preclinical testing. A pharmaceutical scientist with more than 15 years in oncology R&D and global medical affairs, she previously served as Chief Development Officer at Mural Oncology, where she helped lead the company's public offering, and as VP, Head of Clinical Development, Oncology at Alkermes. She holds a Ph.D. in pharmaceutical sciences with a focus on pharmacogenomics from Virginia Commonwealth University.
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.